Case Study: Advocacy for an Oncology Drug in Europe
Introduction
Securing market access for innovative oncology drugs is challenging, particularly when high costs and competition come into play. An innovative biotech company enlisted Pro Pharma Research Organization (PPRO) to advocate for a new oncology drug in Europe. PPRO aimed to demonstrate the drug's unique clinical and economic value to ensure reimbursement inclusion. Through strategic stakeholder engagement and scientific advocacy, PPRO set out to improve patient access to this life-saving treatment.
Objectives
- Obtain favorable HTA reviews and reimbursement for the oncology drug in key European markets.
- Highlight the drug’s superior efficacy and long-term benefits over existing treatments.
- Collaborate with patient advocacy groups to drive awareness and support for reimbursement.
Strategy
PPRO devised a strategy centered on scientific advocacy, which included:
- Economic Modeling: PPRO built a comprehensive cost-effectiveness model comparing the new drug to existing treatments. This model illustrated how the drug, though more expensive initially, resulted in significant long-term savings due to reduced hospital stays, fewer adverse events, and better patient outcomes.
- Targeted Stakeholder Engagement: PPRO organized meetings with health agencies, policymakers, and reimbursement bodies, presenting detailed evidence of the drug's impact. These discussions were supported by data from pivotal clinical trials and expert opinions from leading oncologists.¿
- Collaboration with Patient Advocacy Groups: PPRO partnered with oncology patient groups to increase awareness of the drug's life-saving potential. These groups played an instrumental role in influencing public opinion and advocating for access to the treatment.
- Omni-Channel Communication: The campaign included a digital communication strategy through online platforms, virtual conferences, and webinars that targeted healthcare professionals, patients, and policy stakeholders. This approach ensured continuous visibility for the drug and its benefits.
Results
- Successful Reimbursement: The drug was successfully included in reimbursement frameworks in key European markets.
- Increased Adoption: The comprehensive cost-effectiveness analysis convinced payers to invest in the treatment, leading to widespread adoption.
- Strong Patient Advocacy Support: The involvement of patient groups helped push reimbursement negotiations over the line, ensuring the drug was accessible to more patients.
- Reduced Healthcare Costs: Real-world data collected post-launch demonstrated a reduction in healthcare costs, validating the drug’s long-term value and strengthening its market position.
Conclusion
This case study demonstrate how Pro Pharma Research Organization’s scientific advocacy campaigns can successfully navigate complex healthcare environments to achieve market access and favorable reimbursement outcomes. By leveraging clinical evidence, engaging key stakeholders, and using region-specific insights, PPRO enables pharmaceutical and biotech companies to introduce innovative treatments while maximizing their impact on patient health.
Through its Scientific Advocacy services in Mexico, Brazil, and LATAM (Micro Advocacy Networks, Medical Science Liaison, Medical Science Advocacy, Health Science Advocacy, and an Omni Channel Contact Center, as well as in other global regions, Pro Pharma Research Organization continues to play a pivotal role in shaping the future of pharmaceutical market access globally.
Contact us
Ready to learn more about how we can help you navigate the complexities of market access and reimbursement for innovative therapies? Don’t hesitate to reach out to us for more information!
